What was the overall market valuation of the US HIV diagnosis-treatment market in 2024?

The overall market valuation was $586.46 Million in 2024. Read More

What is the projected market valuation for the US HIV diagnosis-treatment market by 2035?

The projected valuation for 2035 is $1216.51 Million. Read More

What is the expected CAGR for the US HIV diagnosis-treatment market during the forecast period 2025 - 2035?

The expected CAGR during the forecast period 2025 - 2035 is 6.86%. Read More

Which companies are considered key players in the US HIV diagnosis-treatment market?

Key players include AbbVie, Gilead Sciences, Bristol-Myers Squibb, Roche, Johnson & Johnson, Merck & Co., ViiV Healthcare, AstraZeneca, and Sanofi. Read More

What were the revenue ranges for ELISA tests in the US HIV diagnosis segment?

The revenue range for ELISA tests was $200.0 Million to $400.0 Million. Read More

How much revenue did saliva tests generate in the US HIV diagnosis segment?

Saliva tests generated revenue between $100.0 Million and $200.0 Million. Read More

What is the revenue range for NRTIs in the US HIV treatment segment?

The revenue range for NRTIs was $150.0 Million to $300.0 Million. Read More

What were the revenue figures for integrase inhibitors in the US HIV treatment segment?

Integrase inhibitors generated revenue between $100.0 Million and $200.0 Million. Read More

What is the revenue range for viral load tests in the US HIV diagnosis segment?

The revenue range for viral load tests was $150.0 Million to $300.0 Million. Read More

What were the revenue figures for protease inhibitors in the US HIV treatment segment?

Protease inhibitors generated revenue between $80.0 Million and $160.0 Million. Read More

US HIV Diagnosis Treatment Market

ID: MRFR/Pharma/17469-CR

100 Pages

Satyendra Maurya

Last Updated: April 06, 2026

US HIV Diagnosis Treatment Market Research Report By Diagnosis (ELISA Test, Saliva Tests, Viral Load Test, Western Blot, Others), By Treatment (Protease inhibitors (PIs), Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs), Entry or fusion inhibitors, Integrase inhibitors, Others), By Region - Growth & Industry Forecast 2025 To 2035

US HIV Diagnosis Treatment Market Infographic

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Construction, BY Diagnosis (USD Million)
  1. 4.1.1 ELISA Test
  2. 4.1.2 Saliva Tests
  3. 4.1.3 Viral Load Test
  4. 4.1.4 Western Blot
  5. 4.1.5 Others
2. 4.2 Construction, BY Treatment (USD Million)
  1. 4.2.1 Protease inhibitors (PIs)
  2. 4.2.2 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  3. 4.2.3 Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs)
  4. 4.2.4 Entry or fusion inhibitors
  5. 4.2.5 Integrase inhibitors
  6. 4.2.6 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Construction
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Construction
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 AbbVie (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Gilead Sciences (US)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Roche (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Merck & Co. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 ViiV Healthcare (GB)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 AstraZeneca (GB)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Sanofi (FR)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY DIAGNOSIS
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 KEY BUYING CRITERIA OF CONSTRUCTION
5. 6.5 RESEARCH PROCESS OF MRFR
6. 6.6 DRO ANALYSIS OF CONSTRUCTION
7. 6.7 DRIVERS IMPACT ANALYSIS: CONSTRUCTION
8. 6.8 RESTRAINTS IMPACT ANALYSIS: CONSTRUCTION
9. 6.9 SUPPLY / VALUE CHAIN: CONSTRUCTION
10. 6.10 CONSTRUCTION, BY DIAGNOSIS, 2024 (% SHARE)
11. 6.11 CONSTRUCTION, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
12. 6.12 CONSTRUCTION, BY TREATMENT, 2024 (% SHARE)
13. 6.13 CONSTRUCTION, BY TREATMENT, 2024 TO 2035 (USD Million)
14. 6.14 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY DIAGNOSIS, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Construction Market Segmentation

Construction By Diagnosis (USD Million, 2025-2035)

ELISA Test
Saliva Tests
Viral Load Test
Western Blot
Others

Construction By Treatment (USD Million, 2025-2035)

Protease inhibitors (PIs)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs)
Entry or fusion inhibitors
Integrase inhibitors
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”